Publications by authors named "Jochen Gleissner"
Background: Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC may not be necessary.
Methods: In this exploratory phase 2 study, mCRPC patients were randomized with a 1:1 ratio to receive either continued ADT plus AA + P (Arm A) or AA + P alone (Arm B).
Non-metastatic castration-resistant prostate carcinoma (M0CRPC) is associated with an increased risk of progression and mortality, especially if the prostate-specific antigen doubling time is short (PSADT ≤ 10 months). The risk of progression and mortality increases even further if the disease progresses to the metastatic stage (mCRPC). The androgen receptor inhibitors apalutamide, darolutamide and enzalutamide, each in combination with androgen deprivation therapy (ADT), are available for the treatment of patients with high-risk M0CRPC.
View Article and Find Full Text PDFResidual androgen production causes tumor progression in metastatic, castration-resistant prostate cancer (mCRPC) patients. Abiraterone acetate (AA), a prodrug of abiraterone, is an oral CYP-17 inhibitor that blocks androgen production. It was hypothesized that adherence-enhancing measures (AEM) might be beneficial for mCRPC patients receiving abiraterone acetate plus prednisone (AA + P).
View Article and Find Full Text PDFArticle Synopsis
- The study is investigating noninvasive follow-up methods for patients with low-grade nonmuscle invasive bladder cancer (NMIBC) to reduce overdiagnosis and overtreatment.
- Researchers are creating a prospective randomized trial called "UroFollow" to assess the effectiveness of urine marker-guided follow-up compared to traditional cystoscopy.
- Initial findings suggest that specific cell-based urine markers may offer higher sensitivity for detecting low-grade NMIBC compared to other methods, and the trial will compare these noninvasive approaches over three years.
In their daily routine, urologists in general and uro-oncologists in particular are often confronted with non-urologic complications. To meet the need for measures of symptom control at the interface between genuine urologic and general palliative care, it is necessary for the partners from special outpatient palliative care (SAPV), general outpatient palliative care (AAPV), medical centres and other service units to cooperate. There are a significant number of urological practitioners who have completed trainings in palliative care or passed an exam as 'qualified palliative physician (QPA)'.
View Article and Find Full Text PDFPurpose: The ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients.
Methods: This prospective, single-arm, open-label study in bisphosphonate-naive (≥6 months) patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) enrolled at 98 German sites (May 2006 to July 2008) investigated the effect of ZOL (4 mg intravenously every 4 weeks×4 months, with a final follow-up at 12 months) on bone-marker levels. Secondary assessments: skeletal-related event (SRE) rate, pain, quality of life (QoL), and prostate-specific antigen levels.
Introduction: The prevalence of erectile dysfunction (ED) is increased in men with metabolic syndrome compared with the general population.
Aim: The aim of this study was to evaluate the efficacy and safety of vardenafil vs. placebo in men who had ED and metabolic syndrome.